CORE Diagnostics to launch liquid biopsy test for oncology throughout India

New Delhi, July 20 : CORE Diagnostics, the clinical diagnostics laboratory focused on bringing advanced diagnostics techniques and expertise to India, announced collaboration with Star Health Network, Inc., a New York-based healthcare company. The agreement extends to the use of the Celsee diagnostics' liquid biopsy test in India. CORE Diagnostics will add the CTC test to their expanding list of tests, and market the product to the patient population across India. Primary and metastatic tumors shed cells into the bloodstream. These are called circulating tumor cells [CTC]. The Celsee CTC test detects cancer cells in the blood stream and determines whether cancer treatment is working, or the disease is spreading. The test is a valuable aid to oncologists in evaluating prognosis of metastatic breast, colorectal, prostate and lung cancers. Zoya Brar, Founder (and) Managing Director, CORE Diagnostics, said, "We are happy to partner with Star Health Network, and to add this state-of-the-art CTC test to our growing menu. Oncology is a rapidly developing field with a focus on research and early detection. We sincerely hope that this diagnostic test will help oncologists plan the best possible targeted treatments, for the most successful patient outcomes." CTC is an instrumental technology in aiding cancer treatment. Star Health Network is helping commercialize Celsee CTC technology across India and is excited to forge the collaboration with CORE Diagnostics.